What is the most likely etiology of new‑onset tinnitus in a 55‑year‑old man with chronic systolic heart failure, chronic obstructive pulmonary disease, hypertension, osteoarthritis, who started furosemide and lisinopril one week ago and has normal Weber and Rinne testing without hearing loss, vertigo, or neurologic deficits?

Ototoxic Medication Use (Furosemide)

The most likely etiology of this patient's tinnitus is ototoxic medication use, specifically from furosemide, which he started one week ago—a timeline that directly correlates with his symptom onset. 1

Clinical Reasoning for Furosemide as the Culprit

Furosemide is a well-established ototoxic agent that causes tinnitus through disruption of cochlear function. The FDA drug label explicitly warns that "cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported" with furosemide use. 1 The mechanism involves:

• Rapid decrease of the endocochlear potential following furosemide administration 2
• Interference with strial adenylate cyclase and Na+/K+-ATPase in the stria vascularis 3
• Abolishment of blood flow in vessels supplying the lateral wall of the cochlea, leading to strial ischemia 3

The temporal relationship is critical here: This patient's tinnitus began 2 days ago, and he started furosemide exactly 1 week ago—a classic presentation for loop diuretic ototoxicity. 1, 2

Risk Factors Present in This Patient

This patient has multiple risk factors that increase his susceptibility to furosemide ototoxicity:

• Concomitant use of aspirin and clopidogrel (antiplatelet agents that may affect cochlear blood flow) 1
• Chronic systolic heart failure requiring aggressive diuresis 4
• Age 55 years (older patients have increased vulnerability) 5
• Recent initiation of furosemide (rapid changes in fluid status) 1

The FDA label specifically warns that ototoxicity is associated with rapid injection, severe renal impairment, higher than recommended doses, hypoproteinemia, or concomitant therapy with other ototoxic drugs. 1 While this patient received oral furosemide, the combination of heart failure (potential hypoproteinemia) and multiple medications creates a higher-risk scenario.

Why the Other Diagnoses Are Unlikely

Ménière disease is excluded because:

• No episodic vertigo (Ménière requires recurrent vertigo attacks lasting 20 minutes to 12 hours) 4
• No fluctuating hearing loss (patient explicitly denies hearing loss) 4
• No aural fullness reported 4
• Normal Weber and Rinne testing (Ménière typically shows asymmetric sensorineural hearing loss) 4

Presbycusis is excluded because:

• Acute 2-day onset (presbycusis is gradual, age-related hearing loss over years) 6
• No documented hearing loss on examination 6
• Age 55 is relatively young for significant presbycusis 6

Vestibular schwannoma is excluded because:

• Bilateral normal Weber test (schwannoma causes unilateral hearing loss with lateralization) 6, 7
• No asymmetric hearing loss 6, 7
• No cranial nerve deficits (large schwannomas cause facial nerve or trigeminal involvement) 6
• Acute onset (schwannomas cause gradual, progressive symptoms over months to years) 7

Management Recommendations

The immediate next step is to discuss with the prescribing physician whether furosemide can be discontinued, dose-reduced, or switched to an alternative diuretic with lower ototoxic potential. 1, 5

If diuresis must continue:

• Consider switching to a thiazide diuretic (hydrochlorothiazide, which he is already taking, has lower ototoxic risk) 4
• Avoid combining furosemide with other ototoxic agents (aminoglycosides, aspirin in high doses) 1, 8
• Monitor electrolytes closely (hypokalemia and metabolic alkalosis can worsen outcomes) 4

Audiologic evaluation should be obtained to document baseline hearing and monitor for progression, even though the patient currently denies hearing loss. 9, 6 Subclinical hearing loss may be present on formal audiometry. 6

Reassure the patient that furosemide-induced tinnitus is typically reversible when the medication is discontinued or the dose is reduced. 1, 2 However, permanent damage can occur with prolonged exposure or when combined with other ototoxic drugs. 8, 2

Critical Pitfall to Avoid

Do not continue furosemide at the current dose without addressing the tinnitus, as this represents a warning sign of cochlear toxicity that may progress to permanent hearing loss if the medication is continued. 1, 3 The FDA label explicitly states that "if increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued." 1 While this patient's tinnitus (not azotemia) is the presenting concern, the principle of recognizing early ototoxicity and adjusting therapy applies equally.

The combination of loop diuretics with aminoglycosides is particularly dangerous and should be avoided, as the aminoglycoside increases cell membrane permeability, allowing the loop diuretic to penetrate inner ear cells in higher concentrations. 8 This patient is not currently on aminoglycosides, but this combination must be avoided if infection develops.